Piper Jaffray Downgrades Anthera Pharma (ANTH) to Underweight; PT $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Anthera Pharma (ANTH) PT Lowered to $0.50 at Jefferies
March 12, 2018 11:17 AM EDTJefferies lowered its price target on Anthera Pharma (NASDAQ: ANTH) to $0.50 (from $2.00) while maintaining a Hold rating.
... MoreAnthera Pharma (ANTH) Phase 3 Clinical Study of Sollpura Did Not Meet Primary Endpoint
March 12, 2018 8:01 AM EDTAnthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that Sollpura did not meet the non-inferiority margin of the CFA primary endpoint in the RESULT Phase 3 clinical study of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis.
The design of the RESULT study was based on the outcome of the previous Phase 3 SOLUTION study and included a higher starting dose and more aggressive dose optimizations based on clinical signs and symptoms of malabsorption. In the RESULT... More
